# Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

> **NCT04502017** · PHASE4 · UNKNOWN · sponsor: **Texas Cardiac Arrhythmia Research Foundation** · enrollment: 360 (estimated)

## Conditions studied

- Device-Related Thrombosis
- Atrial Fibrillation
- Left Atrial Appendage Occlusion

## Interventions

- **DRUG:** ASA plus Clopidogrel
- **DRUG:** Genetic-Tailored AntiThrombotic Strategy
- **DRUG:** Half-Dose of novel OAC

## Key facts

- **NCT ID:** NCT04502017
- **Lead sponsor:** Texas Cardiac Arrhythmia Research Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2020-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04502017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04502017, "Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04502017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*